Evidence map›Paper›PMID 18986766›Full record

ArticlePain2008

Inhibition of the ubiquitin-proteasome activity prevents glutamate transporter degradation and morphine tolerance.

Liling Yang, Shuxing Wang, Grewo Lim, Backil Sung, Qing Zeng, Jianren Mao

Abstract read
In one paragraph

Article in Pain, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Involvement of protein degradation by the ubiquitin proteasome system in opiate addictive behaviors.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Liling YangMGH Center for Translational Pain Research, Department of Anesthesia and Critical Care, Massachusetts General Hospital, Harvard Medical School, WACC 324, 15 Parkman Street, Boston, MA 02114, USA.
Shuxing Wang
Grewo Lim
Backil Sung
Qing Zeng
Jianren Mao
Harvard University · USMassachusetts General Hospital · US

Funding

COMORBIDITY BETWEEN DEPRESSION AND OROFACIAL PAINR01DE018538 · NIDCR · MASSACHUSETTS GENERAL HOSPITAL · PI MAO, JIANREN · 2007 to 2011
$2.0M
Central Mechanisms of Orofacial PainR01DE018214 · NIDCR · MASSACHUSETTS GENERAL HOSPITAL · PI MAO, JIANREN · 2008 to 2012
$1.7M
Glutamate Uptake &the Pathogenesis of Neuropathic PainR01NS045681 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI MAO, JIANREN · 2004 to 2007
$1.4M
NIDCR NIH HHS R01 DE018214NIDCR NIH HHS R01 DE018538NIDCR NIH HHS R01 DE 18214NIDCR NIH HHS R01 DE18538NINDS NIH HHS R01 NS045681NINDS NIH HHS R01 NS45681
6 · The paper itself

Abstract

Glutamate transporters play a crucial role in physiological glutamate homeostasis and neurotoxicity. Recently, we have shown that downregulation of glutamate transporters after chronic morphine exposure contributed to the development of morphine tolerance. In the present study, we examined whether regulation of the glutamate transporter expression with the proposed proteasome inhibitor MG-132 would contribute to the development of tolerance to repeated intrathecal (twice daily x 7 days) morphine administration in rats. The results showed that MG-132 (5 nmol) given intrathecally blocked morphine-induced glutamate transporter downregulation and the decrease in glutamate uptake activity within the spinal cord dorsal horn. Co-administration of morphine (15 nmol) with MG-132 (vehicle=1<2.5<5=10 nmol) also dose-dependently prevented the development of morphine tolerance in rats. These findings suggest that prevention of spinal glutamate transporter downregulation may regulate the glutamatergic function that has been implicated in the development of morphine tolerance. The possible relationship between MG-132-mediated regulation of glutamate transporters, ubiquitin-proteasome system, and the cellular mechanisms of morphine tolerance is discussed in light of these findings.

Indexed as

Analgesics, OpioidAnimalsCysteine Proteinase InhibitorsDown-RegulationDrug ToleranceGlutamic AcidInjections, SpinalLeupeptinsMaleMorphinePainPosterior Horn CellsProteasome Endopeptidase ComplexProteasome InhibitorsRatsRats, Sprague-DawleyAnalgesics, Opioidbenzyloxycarbonylleucyl-leucyl-leucine aldehydeCysteine Proteinase InhibitorsGlutamic AcidLeupeptinsMorphineProteasome Endopeptidase ComplexProteasome InhibitorsUbiquitinVesicular Glutamate Transport Proteins

Identifiers

PMID18986766
PMCPMC3454498
OpenAlexW2018886245

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.